The prevalence of human herpesvirus-7 in renal transplant recipients is unaffected by oral or intravenous ganciclovir

Journal of Infectious Diseases

Volumn 181, Issue 5, 2000, Pages 1557-1561

  Brennan, Daniel C ^a   Storch, Gregory A ^a   Singer, Gary G ^a   Lee, Linda ^a,b   Rueda, Jose ^a   Schnitzler, Mark A ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Medical Center Clinic Pensacola   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GANCICLOVIR;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTION; HIGH RISK PATIENT; HUMAN; HUMAN CELL; HUMAN HERPESVIRUS 7; KIDNEY TRANSPLANTATION; LEUKOCYTE; MAJOR CLINICAL STUDY; POSTOPERATIVE INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; VIREMIA; VIRUS RESISTANCE;

ADMINISTRATION, ORAL; ADULT; ANTIVIRAL AGENTS; CYTOMEGALOVIRUS INFECTIONS; GANCICLOVIR; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 7, HUMAN; HUMANS; INJECTIONS, INTRAVENOUS; KIDNEY TRANSPLANTATION; POLYMERASE CHAIN REACTION; POSTOPERATIVE COMPLICATIONS; PREVALENCE; TIME FACTORS; VIREMIA;

EID: 0034043961     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315477     Document Type: Article

References (23)

1. 1. Torigoe S, Kumamoto T, Koide W, Taya K, Yamanishi K. Clinical manifestations associated with human herpesvirus 7 infection. Arch Dis Child 1995;72:518-19.
2. 2. Portolani M, Cermelli C, Mirandola P, Di Luca D. Isolation of human herpesvirus 7 from an infant with febrile syndrome. J Med Virol 1995; 45:282-3.
3. 3. Yalcin S, Karpuzoglu T, Suleymanlar G, et al. Human herpesvirus 6 and human herpesvirus 7 infections in renal transplant recipients and healthy adults in Turkey. Arch Virol 1994;136:183-90.
4. 4. Di Luca D, Zorzenon M, Mirandola P, Colle R, Botta G, Cassai E. Human herpesvirus 6 and human herpesvirus 7 in chronic fatigue syndrome. J Clin Microbiol 1995;33(6):1660-4.
5. 5. Drago F, Ranieri E, Malaguti F, Battifoglia ML, Losi E, Rebora A. Human herpesvirus 7 in patients with pityriasis rosea. Dermatology 1997;195: 374-8.
6. 6. Crowley R, Secchiero P, Zella D, Cara A, Gallo R, Lusso, P. Interference between human herpesvirus 7 and HIV-1 in mononuclear phagocytes. J Immunol 1996;156:2004-8.
7. 7. Osman H, Peiris J, Taylor C, Warwicker P, Jarrett R, Madeley C. "Cytomegalovirus disease" in renal allograft recipients: is human herpesvirus 7 a co-factor for disease progression? J Med Virol 1996;48:295-301.
8. 8. Singh N, Carrigan D. Human herpesvirus-6 in transplantation: an emerging pathogen. Ann Intern Med 1996;124:1065-71.
9. 9. Brennan DC, Garlock KA, Lippmann BA, et al. Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. J Am Soc Nephrol 1997;8:118-25.
10. 10. Brennan DC, Garlock KA, Singer GG, et al. Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 1997;64:1843-6.
11. 11. Lavelle J, Follansbee S, Trapnell CB, et al. Effect of food on the relative bioavailability of oral ganciclovir. J Clin Pharmacol 1996;36:238-41.
12. 12. Wilborn F, Schmidt CA, Lorenz F, Peng R, Gelderblom H, Siegert W. Human herpesvirus type 7 in blood donors: detection by the polymerase chain reaction. J Med Virol 1995;47:65.
13. 13. Berneman ZN, Ablashi DV, Li G, et al. Human herpesvirus 7 is a T-lymphotrophic virus and is related to, but significantly different from, human herpesvirus 6 and human cytomegalovirus. Proc Natl Acad Sci USA 1992;89:10552-6.
14. 14. Kapuscinski J, Skoczylas B. Simple and rapid fluorimetric method for DNA microassay. Anal Biochem 1977;83:252.
15. 15. Kapuscinski J, Yanagi K. Selective staining by 4,6-diamidino-2-phenylindole of nanogram quantities of DNA in the presence of RNA on gels. Nucleic Acids Res 1979;6:3535.
16. 16. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-70.
17. 17. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457.
18. 18. Yoshida M, Yamada M, Tsukazaki T, Chatterjee S, Lakeman FD, Nii S, Whitley RJ. Comparison of antiviral compounds against human herpesvirus 6 and 7. Antiviral Res 1998;40:73-84.
19. 19. Crumpacker CS. Ganciclovir. N Engl J Med 1996;335:721-9.
20. 20. Roberts TC, Buller RS, Gaudreault-Keener M, et al. Effects of storage temperature and time on qualitative and quantitative detection of cytomegalovirus in blood specimens by shell vial culture and PCR. J Clin Microbiol 1997;35:2224-8.
21. 21. Pescovitz MD, Pruett TL, Gonwa T, et al. Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. Transplantation 1998;66(8):1104-7.
22. 22. Piketty C, Bardin C, Gilquin J, Mahe V, Kazatchkine MD, Chast F. Low plasma concentrations achieved with conventional schedules of administration of ganciclovir in patients with AIDS. J Infect Dis 1996;174: 188-90.
23. 23. Wolfe EJ, Mathur V, Tomlanovich S, et al. Pharmacokinetics of mycophenolate mofetil and iv ganciclovir alone and in combination in renal transplant recipients. Pharmacotherapy 1997;17(3):591-8.